The infectious disease segment has always been a key pillar of the In Vitro Diagnostics (IVD) Market, but it has achieved unprecedented prominence and investment due to the recent public health crises. IVD tests, including rapid antigen tests, highly sensitive PCR assays (Molecular Diagnostics), and antibody tests (Immunodiagnostics), are the first-line tools for surveillance, diagnosis, containment, and tracking of outbreaks, ranging from influenza and HIV to emerging pathogens. The massive scale-up of manufacturing capacity for these tests has dramatically increased the total market volume and technology adoption globally.

Beyond pandemic response, the chronic and endemic infectious disease testing market remains robust. This includes the continuous demand for diagnostics for HIV, Hepatitis B and C, Tuberculosis (TB), and hospital-acquired infections (HAIs). A significant driver in this area is the global fight against Antimicrobial Resistance (AMR). Diagnostics are crucial for identifying pathogens and determining their resistance patterns quickly, guiding clinicians away from broad-spectrum antibiotics to targeted treatments. The need for rapid and accurate diagnosis of viral and bacterial infections in centralized laboratories and through Point-of-Care Testing (POCT) systems ensures sustained investment in innovation. As global health security becomes a permanent priority for governments and international organizations, the infectious disease testing segment of the IVD market is poised for long-term strategic growth. This segment is constantly evolving, incorporating multiplex testing and automation to handle diverse and rapidly changing demands. For detailed figures on the infectious disease testing market size, technology adoption rates, and post-pandemic outlook, refer to the In Vitro Diagnostics Market Research Report.